In trials, GSK’s vaccine significantly reduced ... identified a protein in RSV a decade ago that looked like a promising antigen for vaccine development. Both Arexvy and Abrysvo target this ...

GSK's vaccine has just hit the mark in a phase ... all awarded by the European Patent Office and covering recombinant RSV antigens and compositions and methods for making them.

Non-mRNA adult RSV vaccines developed by Pfizer and GSK gained FDA approval in May ... not the immunity inducing antigen itself, but instructions for cells to produce the antigen then display ...

Among adults aged 75 and older, RSV was linked to a substantial burden of hospitalizations, ICU admissions, and in-hospital deaths before vaccines were available.

and the clinical effectiveness of palivizumab and motavizumab validate RSV F protein as an attractive vaccine antigen. These epidemiological and clinical data combined with recent advances in RSV ...

The case is the latest filed by GSK against Pfizer over technology used in its vaccines. Last year, GSK sued Pfizer, alleging that Pfizer’s RSV vaccine Abrysvo infringed upon GSK’s patents for ...

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

AMA Update covers a range of health care topics affecting the lives of physicians, residents, medical students and patients. From private practice and health system leaders to scientists and public ...

Jan 7 (Reuters) - GSK (GSK.L), opens new tab and Pfizer's (PFE.N), opens new tab respiratory syncytial virus (RSV) vaccines will carry warnings that they can increase the risk of developing a rare ...

Moderna is girding itself for a commercial battle with two of the largest vaccine makers in the world—Pfizer and GSK—with the expected launch of its respiratory syncytial virus vaccine later ...

GSK’s marketed vaccines target infectious diseases at every stage of life, protecting people from meningitis, shingles, respiratory syncytial virus (RSV), flu, polio and many more. Every day ...

“I am very proud to say that, as of 2023 GSK now has two approved and recommended RSV vaccines for adults ... an early start to identifying antigens. Dr. Piyali Mukherjee, Vice President, Head of ...